Ameriprise’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-12,399
| Closed | -$241K | – | 4026 |
|
|
2023
Q3 | $241K | Sell |
12,399
-36,870
| -75% | -$417K | ﹤0.01% | 3645 |
|
|
2023
Q2 | $545K | Buy |
49,269
+6,055
| +14% | +$84.4K | ﹤0.01% | 3400 |
|
|
2023
Q1 | $580K | Buy |
43,214
+1,514
| +4% | +$26.2K | ﹤0.01% | 3367 |
|
|
2022
Q4 | $510K | Sell |
41,700
-47,493
| -53% | -$673K | ﹤0.01% | 3401 |
|
|
2022
Q3 | $1.24M | Sell |
89,193
-5,918
| -6% | -$95.3K | ﹤0.01% | 3010 |
|
|
2022
Q2 | $1.31M | Buy |
95,111
+7,990
| +9% | +$128K | ﹤0.01% | 2999 |
|
|
2022
Q1 | $1.42M | Buy |
87,121
+9,428
| +12% | +$148K | ﹤0.01% | 3064 |
|
|
2021
Q4 | $1.26M | Buy |
77,693
+57,168
| +279% | +$964K | ﹤0.01% | 3148 |
|
|
2021
Q3 | $305K | Sell |
20,525
-23,593
| -53% | -$377K | ﹤0.01% | 3565 |
|
|
2021
Q2 | $881K | Buy |
44,118
+20,709
| +88% | +$411K | ﹤0.01% | 3269 |
|
|
2021
Q1 | $540K | Sell |
23,409
-1,187,123
| -98% | -$33.1M | ﹤0.01% | 3370 |
|
|
2020
Q4 | $29.9M | Buy |
1,210,532
+349,254
| +41% | +$11.6M | 0.01% | 988 |
|
|
2020
Q3 | $35.7M | Buy |
861,278
+694,080
| +415% | +$31.9M | 0.01% | 778 |
|
|
2020
Q2 | $8.01M | Sell |
167,198
-229,836
| -58% | -$17.8M | ﹤0.01% | 1699 |
|
|
2020
Q1 | $25M | Buy |
397,034
+129,804
| +49% | +$11.7M | 0.01% | 826 |
|
|
2019
Q4 | $33.1M | Buy |
267,230
+71,818
| +37% | +$6.43M | 0.01% | 888 |
|
|
2019
Q3 | $13M | Buy |
195,412
+68,428
| +54% | +$4.59M | 0.01% | 1487 |
|
|
2019
Q2 | $10.1M | Buy |
126,984
+92,313
| +266% | +$8.26M | ﹤0.01% | 1729 |
|
|
2019
Q1 | $3.87M | Buy |
34,671
+160
| +0.5% | +$17.5K | ﹤0.01% | 2387 |
|
|
2018
Q4 | $3.48M | Sell |
34,511
-18,003
| -34% | -$1.87M | ﹤0.01% | 2357 |
|
|
2018
Q3 | $6.64M | Buy |
52,514
+10,113
| +24% | +$1.07M | ﹤0.01% | 2164 |
|
|
2018
Q2 | $3.56M | Sell |
42,401
-46,947
| -53% | -$3.44M | ﹤0.01% | 2459 |
|
|
2018
Q1 | $5.5M | Sell |
89,348
-62,434
| -41% | -$3.76M | ﹤0.01% | 2106 |
|
|
2017
Q4 | $8.87M | Sell |
151,782
-1,298,730
| -90% | -$81.9M | ﹤0.01% | 1702 |
|
|
2017
Q3 | $84.2M | Sell |
1,450,512
-1,126,217
| -44% | -$121M | 0.04% | 406 |
|
|
2017
Q2 | $312M | Sell |
2,576,729
-313,813
| -11% | -$36.4M | 0.16% | 145 |
|
|
2017
Q1 | $327M | Buy |
2,890,542
+382,642
| +15% | +$44.7M | 0.17% | 135 |
|
|
2016
Q4 | $272M | Sell |
2,507,900
-118,100
| -4% | -$14.1M | 0.15% | 140 |
|
|
2016
Q3 | $432M | Sell |
2,626,000
-380,293
| -13% | -$60M | 0.24% | 87 |
|
|
2016
Q2 | $429M | Buy |
3,006,293
+74,253
| +3% | +$10.8M | 0.25% | 83 |
|
|
2016
Q1 | $377M | Buy |
2,932,040
+68,971
| +2% | +$8.14M | 0.22% | 96 |
|
|
2015
Q4 | $428M | Buy |
2,863,069
+1,016,175
| +55% | +$172M | 0.25% | 86 |
|
|
2015
Q3 | $306M | Buy |
1,846,894
+350,815
| +23% | +$77.2M | 0.19% | 108 |
|
|
2015
Q2 | $361M | Buy |
1,496,079
+672,471
| +82% | +$179M | 0.21% | 108 |
|
|
2015
Q1 | $232M | Buy |
823,608
+745,603
| +956% | +$161M | 0.13% | 156 |
|
|
2014
Q4 | $12.2M | Sell |
78,005
-12,554
| -14% | -$2.32M | 0.01% | 1343 |
|
|
2014
Q3 | $21.4M | Buy |
90,559
+29,431
| +48% | +$7.5M | 0.01% | 924 |
|
|
2014
Q2 | $14.5M | Buy |
61,128
+43,126
| +240% | +$11.4M | 0.01% | 1260 |
|
|
2014
Q1 | $5.94M | Buy |
18,002
+2,353
| +15% | +$794K | ﹤0.01% | 1903 |
|
|
2013
Q4 | $1.07M | Buy |
15,649
+3,652
| +30% | +$211K | ﹤0.01% | 2639 |
|
|
2013
Q3 | $828K | Buy |
11,997
+11,606
| +2,968% | +$573K | ﹤0.01% | 2737 |
|
|
2013
Q2 | $18K | Buy |
+391
| New | +$13.4K | ﹤0.01% | 4363 |
|
Ameriprise's ICPT Position: Q4 2023 in Review
Ameriprise sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 12,399 shares — an estimated $241K sold.
Ameriprise first reported a position in ICPT in Q2 2013 and held it in 42 quarters. The position peaked at $432M in Q3 2016. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Ameriprise reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Ameriprise sold 12,399 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $241K.
- Ameriprise first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 42 quarters.
- Ameriprise's Intercept Pharmaceuticals, Inc. position peaked at $432M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.